Published on

Toxicology – Valproic Acid


Description

Valproic acid is an anticonvulsant medication used for the treatment of seizure disorders, bipolar affective disorder, and migraine headache.


Forms and Uses

Pharmaceutical preparations include sodium valproate and divalproex sodium.

For seizure disorders, the usual adult starting dose is approximately 15 mg/kg/day orally, divided into one to three doses, with gradual increases up to a maximum of about 60 mg/kg/day.

For migraine prophylaxis, adult dosing generally ranges from 250–1,000 mg/day orally.

For mania, an adult starting dose of approximately 750 mg/day may be used and titrated upward, with a maximum of about 60 mg/kg/day divided into several doses.


Toxic Dose

The toxic dose is variable.

Adverse effects may occasionally occur at concentrations close to the therapeutic range, particularly in individuals who are not chronically taking valproate.

Severe toxicity, including coma, has been reported after very large pediatric ingestions. One reported infant ingested approximately 750 mg/kg.


Pathophysiology

The exact therapeutic and toxic mechanisms of valproic acid are not completely understood.

One important action is an increase in brain concentrations of:

Gamma-aminobutyric acid (GABA)

which contributes to CNS inhibitory activity.

In overdose, excessive CNS depression becomes the dominant manifestation.


Epidemiology

Valproic acid poisoning is relatively uncommon.

Most overdoses produce mild toxicity, while severe poisoning and death are generally associated with massive ingestions or important coingestants.


Causes

Most significant overdoses are intentional.

In very young children, inappropriate exposure may raise concern for neglect.

In older children, adolescents, or adults, intentional self-poisoning should be considered when appropriate.


Risk Factors

Patients with underlying cardiovascular disease may be more susceptible to severe cardiovascular effects during significant poisoning.


Drug and Disease Interactions

Coadministration with other:

Sedatives, hypnotics, anticonvulsants, or CNS depressants

may increase CNS depression.

Therapeutic use with medications such as:

Cimetidine, ranitidine, aspirin, and isoniazid

may increase valproate concentrations.

Use with some other anticonvulsants may increase concentrations of valproate metabolites and potentially contribute to hepatic injury.


Pregnancy and Lactation

The historical FDA classification listed valproic acid as Pregnancy Category D.

Evidence of fetal risk exists.

Valproic acid is a known human teratogen and has been associated with an increased risk of:

Neural tube defects, particularly spina bifida

and

Minor craniofacial abnormalities.

The historical estimate for spina bifida risk was approximately 1%–2%.


Differential Diagnosis

Other toxic causes of CNS depression include:

Barbiturates, other anticonvulsants, ethanol, sedative-hypnotics, and many other CNS depressants.

Non-toxicologic causes include:

Metabolic abnormalities, electrolyte disturbances, intracranial mass or hemorrhage, and infection.


Clinical Features

Mild CNS depression is common after overdose.

With increasing severity, patients may progress to:

Lethargy → coma → respiratory depression → hypotension

Fever is uncommon.


HEENT

Pinpoint pupils have occasionally been reported, although this is not a common finding.


Cardiovascular Effects

Severe overdose may cause:

Profound hypotension

and, rarely:

Cardiac arrest

Cardiac arrest usually occurs secondary to severe respiratory failure or profound systemic toxicity.


Pulmonary Effects

Respiratory depression may progress to respiratory failure in severe poisoning.


Gastrointestinal Effects

Pancreatitis has been reported after severe overdose.

Pancreatitis may also occur as an adverse effect during chronic therapeutic treatment.


Hepatic Effects

Hepatitis may develop during chronic valproic acid therapy and can occasionally be fatal.

This complication occurs particularly in children during the first several months of therapy, especially when multiple anticonvulsants are being used.

After an acute overdose, mild elevations in hepatic enzymes may occasionally occur.


Renal Effects

Acute renal failure is uncommon and is generally associated with severe hypotension or other complications of major poisoning.


Hematologic Effects

Rare hematologic abnormalities after overdose include:

Anemia

Thrombocytopenia

and

Leukopenia

Leukopenia may also occur during chronic therapeutic use.


Fluids and Electrolytes

Rare abnormalities after acute overdose include:

Hypernatremia

and

Hypocalcemia.


Neurologic Effects

CNS depression is the most common neurologic manifestation.

Severity may range from:

Drowsiness and lethargy

to

Profound coma.

Hypertonia and seizures have also been reported after overdose.

Chronic therapeutic use has occasionally been associated with:

Parkinsonian symptoms

and

Cerebellar atrophy.


Acid–Base Effects

Metabolic acidosis may occur in severe poisoning.

This is generally associated with significant hypotension or systemic compromise.


Serum Valproic Acid Concentration

Serum valproic acid concentration is an important investigation.

The historical therapeutic range is:

50–100 μg/mL

Toxic effects may begin to occur when concentrations rise above approximately:

100 μg/mL

although the clinical condition remains important when interpreting the concentration.


Laboratory Evaluation

In patients with altered mental status or significant poisoning, useful tests include:

Serum electrolytes

Glucose

BUN and creatinine

to evaluate metabolic abnormalities and renal function.


Respiratory and Acid–Base Evaluation

Pulse oximetry and arterial blood gases may be useful in symptomatic patients to evaluate:

Hypoxia

Respiratory depression

and

Metabolic acidosis.


Other Anticonvulsant Levels

When multiple anticonvulsants may have been involved, measurement of other anticonvulsant concentrations can help assess the cause of CNS depression.


CBC, Platelets, and Pancreatic Evaluation

In severe poisoning, useful studies may include:

CBC

Platelet count

and

Serum amylase

to assess for bone marrow suppression or pancreatitis.


ECG and Coingestant Screening

An ECG may be obtained in significant overdose.

In deliberate or uncertain ingestions, acetaminophen and salicylate concentrations may be useful to detect occult coingestion.


Additional Diagnostic Testing

Depending on the presentation, additional investigations may include:

Serum ethanol

Urine toxicology screening

Lumbar puncture

Bacterial cultures

Chest radiography

or

Head CT

to evaluate other causes or complications of CNS depression.


Treatment

Management is primarily supportive.

The major priorities are:

Airway protection + respiratory support + hemodynamic support

The dose, formulation, timing of ingestion, and possibility of coingestants should be determined whenever possible.


When to Seek Toxicology Assistance

Poison-center or toxicology consultation is appropriate when:

Coma, respiratory depression, hypotension, or other severe effects develop

or when:

The clinical picture is inconsistent with valproic acid poisoning or important coingestants are suspected.


Referral to a Health-Care Facility

Medical assessment is appropriate when:

Symptoms are present

Intentional overdose is suspected

The history is unreliable

or

Coingestants or underlying disease complicate the presentation.


Admission

ICU-level treatment may be required for patients with:

Significant altered mental status

or

Hemodynamic instability.


Decontamination – Out of Hospital

Vomiting should not be induced.

CNS depression may develop and increase the risk of aspiration.


Decontamination – In Hospital

The historical treatment approach included gastric lavage after a large recent ingestion or when severe effects were present.

Activated charcoal was also recommended after a substantial recent ingestion.


Activated Charcoal

A single dose of activated charcoal was historically used after significant recent ingestion.

Additional doses were sometimes considered when valproate concentrations continued to rise.


Multiple-Dose Activated Charcoal

Case reports suggested that repeated activated charcoal might shorten the elimination half-life.

However, controlled studies were lacking, and routine use was not recommended.

One or two additional doses were sometimes considered when serum valproate concentrations continued to rise.


Whole-Bowel Irrigation

Whole-bowel irrigation was recommended when serum concentrations continued to increase despite initial gastrointestinal decontamination.

It was considered particularly useful after ingestion of:

Enteric-coated products

or

Divalproex-containing preparations.


Hemodialysis

Valproic acid is normally highly protein bound.

At toxic concentrations, however, the proportion of unbound drug increases substantially.

Hemodialysis has been used in severe cases.

Routine use was not recommended in the original text, but it was considered potentially useful in patients with:

Severe poisoning

and

Hemodynamic instability.


Hemoperfusion

Hemoperfusion has also been used in severe valproic acid poisoning.

Routine use was not recommended, but it was considered an option in patients with severe toxicity and hemodynamic instability.


Antidote

There is no specific antidote for valproic acid poisoning.

Treatment is primarily supportive.


Naloxone

Naloxone has occasionally been reported to improve CNS depression after valproic acid overdose.

However, the response has been inconsistent.

The historical adult starting dose was:

Naloxone 2 mg IV


Hypotension

If hypotension is associated with bradycardia, atropine may be considered.

The historical supportive approach included:

10–20 mL/kg of 0.9% saline intravenously

followed by additional fluids as clinically appropriate.

A vasopressor may be added if hypotension persists.


Seizures

Airway patency should first be ensured.

Benzodiazepines are used for initial seizure control.

If seizures persist or recur, another anticonvulsant such as phenobarbital may be added.


Patient Monitoring

Symptomatic patients should have continuous monitoring of:

Respiratory status

and

Cardiac function.

Complications from prolonged hypotension or hypoxia are uncommon when supportive care is provided promptly.


Expected Course and Prognosis

Most patients recover within approximately:

24–48 hours

after mild or moderate poisoning.

Patients with severe CNS depression or hypotension may require:

4–5 days or longer

before full recovery.


Delayed Absorption

A major concern with divalproex sodium is delayed absorption.

Peak serum concentrations and onset of symptoms may be delayed for 8 hours or longer.

This is especially important after ingestion of delayed-release or enteric-coated preparations.


Discharge From the Emergency Department

Asymptomatic patients with declining serum concentrations may be considered for discharge after an adequate observation period.

The original text suggests approximately:

6–8 hours

provided the patient remains clinically well.

Psychiatric evaluation should be completed when indicated.


Discharge From Hospital

Hospitalized patients may be discharged when:

Hypotension has resolved

Respiratory depression has resolved

CNS depression has significantly improved

and

Serum valproate concentrations are decreasing.

Psychiatric evaluation should be completed when appropriate.


Important Pitfalls

A normal or modest early valproate concentration does not necessarily exclude later toxicity.

Divalproex and enteric-coated preparations may produce delayed peaks.


CNS depression should not automatically be attributed to valproic acid.

Other sedatives, anticonvulsants, ethanol, neurologic disease, infection, and metabolic abnormalities should be considered.


Severe hypotension, respiratory depression, or coma require aggressive supportive care.


Serum valproate concentrations should be followed until a clear downward trend is established after a significant overdose.


High-Yield Toxicology Pearls

Valproic acid overdose primarily causes CNS depression.


The typical progression is:

Lethargy → coma → respiratory depression ± hypotension


The historical therapeutic serum range is:

50–100 μg/mL

and toxicity may begin above approximately:

100 μg/mL


Severe overdose may cause:

Profound hypotension

Respiratory failure

Seizures

Metabolic acidosis

Pancreatitis

and rarely:

Bone marrow suppression or acute renal failure.


Valproic acid is usually highly protein bound, but:

Protein binding decreases at toxic concentrations, increasing the free drug fraction.


Delayed-release and divalproex preparations may cause:

Delayed peak concentrations and delayed clinical deterioration.


The main treatment is:

Airway support + respiratory support + hemodynamic support


There is:

No specific antidote.

Naloxone has occasionally improved CNS depression, although responses are inconsistent.


Hemodialysis and hemoperfusion have been used in severe poisoning, particularly when marked toxicity and hemodynamic instability are present.


The most important clinical warning is:

After divalproex overdose, an initially reassuring level does not guarantee safety—the concentration and CNS depression may continue to rise for many hours.



Image description
0 Comments